Antje‐Christine Walz

Author

Also Known As

A Walz, A. Walz, Antje C. Walz, Antje Walz, Antje-Christine WALZ, Antje-Christine Walz, Antje‐Christine Walz, Antje‑Christine Walz, A‐C Walz

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)Roche Pharma AG (Germany)Institut Claudius Regaud Roche (United Kingdom)University of Konstanz

About

Antje‐Christine Walz is an author at Roche (Switzerland) specializing in medicine, pharmacology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.9K
2	Natural Sciences	1	1	38
3	Allergy	1	1	20
4	Biochemistry	1	1	38
5	Biostatistics	1	1	155

Antje‐Christine Walz

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy Carola H. Ries, Michael A. Cannarile, Sabine Hoves, Cancer Cell Cancer TherapyTumor BiologyTumor-associated MacrophagesTumor ImmunologyCancer Immunosurveillance	2014	1.3K
Patient-derived micro-organospheres enable clinical precision oncology Shengli Ding, Carolyn Hsu, Zhaohui Wang, Cell stem cell MedicineBiological MicroenvironmentsLung CancerOncologyRadiation Oncology	2022	178
Influence of molecular size on tissue distribution of antibody fragments Zhe Li, Ben‐Fillippo Krippendorff, Sharad Sharma, mAbs Biodistribution CoefficientsImmunocytochemical TechniqueImmunologyPathologyImmunodominance	2015	155
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors C. Willemien Menke‐van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, Oncotarget	2016	148
Modeling of tumor growth and anticancer effects of combination therapy Gilbert Koch, Antje‐Christine Walz, Gëzim Lahu, Journal of Pharmacokinetics and Pharmacodynamics OncologyMedicineTumor GrowthTumor TargetingAnti-cancer Agent	2009	108
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia Norbert Vey, Jacques Delaunay, Giovanni Martinelli, Oncotarget	2016	94
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations DR Mould, Antje‐Christine Walz, Thierry Lavé, CPT Pharmacometrics & Systems Pharmacology Precision DosingAnticancer Dose SelectionPreclinical Drug EvaluationPhysiologically-based Pharmacokinetic ModelingMedicine	2015	76
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody Christian Augsberger, Gerulf Hänel, Wei Xu, Blood	2021	66
Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach Brian Higgins, Kelli Glenn, Antje‐Christine Walz, Clinical Cancer Research	2014	60
Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies Katharina T. Kroll, Mariana M. Mata, Kimberly A. Homan, Proceedings of the National Academy of Sciences	2023	58

Page 1